Addressing Disparities in CLL Treatment: A Study on Race and Socioeconomic Factors in Community Oncology Settings

Dr. Ira Zackon, a hematologist/oncologist with New York Oncology Hematology and a senior medical director at Ontada, a data science company part of McKesson, recently discussed a study that aimed to uncover racial and socioeconomic disparities in patients with chronic lymphocytic leukemia (CLL). The research focused on comparing CLL outcomes for Black and White patient populations in community oncology settings, analyzing how race and socioeconomic factors may impact treatment and outcomes.

The study analyzed data from over 12,000 patients with CLL from 2015 to 2023. This period coincided with the introduction of new and effective CLL therapies such as Bruton tyrosine kinase (BTK) inhibitors, BCL2 inhibitors, and antibodies. These advancements have significantly improved the lives of patients with CLL. However, the study also aimed to explore how social determinants of health beyond medical treatments can affect patient outcomes.

Researchers utilized the iKnowMed electronic health record system, which is part of the US Oncology Network. By examining data from a large and geographically diverse database over an 8-year period, researchers were able to identify trends in CLL treatment and outcomes. This analysis provided valuable insights into the impact of race and socioeconomic factors on CLL care in real-world community oncology settings.

In conclusion, Dr. Zackon emphasized that this study highlights the importance of addressing social determinants of health when developing treatment plans for patients with CLL in community oncology settings. By taking into account factors such as race and socioeconomic status when providing care, healthcare providers can better tailor their approach to meet the unique needs of each patient.